Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. STXS
STXS logo

STXS Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy Stereotaxis Inc (STXS) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
1.850
1 Day change
1.65%
52 Week Range
3.590
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

Stereotaxis Inc (STXS) is not a strong buy for a beginner, long-term investor at the moment. While the company has shown revenue growth in the latest quarter, its declining net income, EPS, and gross margin raise concerns about its financial health. The technical indicators and options data do not indicate a strong bullish sentiment or immediate upward momentum. With no significant news, analyst updates, or political trading activity to act as a catalyst, holding off on this investment is advisable for now.

Technical Analysis

The MACD is slightly positive but contracting, suggesting weakening momentum. RSI is neutral at 52.035, and moving averages are converging, indicating no clear trend. Key support and resistance levels are close to the current price, with a pivot at 1.972, R1 at 2.083, and S1 at 1.862. Overall, the technical indicators suggest a lack of strong directional movement.

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

The low put-call ratios indicate a lack of bearish sentiment, but the very low trading volume and open interest suggest limited market activity and enthusiasm for the stock.

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
10
Buy
3

Positive Catalysts

  • Revenue increased by 36.31% YoY in the latest quarter, indicating some growth potential.

Neutral/Negative Catalysts

  • Net income dropped by 25.39% YoY, EPS fell by 33.33%, and gross margin declined slightly. No recent news, analyst updates, or political trading activity to drive interest in the stock.

Financial Performance

In Q4 2025, revenue increased to $8.64 million (up 36.31% YoY), but net income dropped to -$5.85 million (down 25.39% YoY), and EPS fell to -0.06 (down 33.33% YoY). Gross margin also declined slightly to 50.07% (down 1.30% YoY).

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target updates available.

Wall Street analysts forecast STXS stock price to rise
5 Analyst Rating
Wall Street analysts forecast STXS stock price to rise
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 1.820
sliders
Low
4
Averages
4.2
High
5
Current: 1.820
sliders
Low
4
Averages
4.2
High
5
Citizens
Outperform
initiated
$4
AI Analysis
2025-12-16
Reason
Citizens
Price Target
$4
AI Analysis
2025-12-16
initiated
Outperform
Reason
Citizens initiated coverage of Stereotaxis with an Outperform rating and $4 price target. Stereotaxis develops robotic platforms for use in endovascular surgeries, the analyst tells investors in a research note. The firm views the company as a "unique micro-cap MedTech name worth owning" due to its key product developments set to be tailwinds for system adoption and improved procedural utilization through 2026.
Roth Capital
NULL
to
Buy
initiated
$4
2025-11-05
Reason
Roth Capital
Price Target
$4
2025-11-05
initiated
NULL
to
Buy
Reason
Roth Capital resumed coverage of Stereotaxis with a Buy rating and $4 price target. The firm believes the company is positioned for long-term revenue growth and profitability from continued adoption of its Robotic Magnetic Navigation technology along with "imminent" regulatory approvals and subsequent commercial launches of its product pipeline.
Unlock Full Analyst Thesis, Get the complete breakdown of rating reason for STXS
Unlock Now

People Also Watch